Spironolactone Use in Patients with Renal Impairment

Contraindications and Precautions

The American Heart Association recommends that spironolactone be contraindicated in patients with a glomerular filtration rate (GFR) less than 30 mL/min/1.73 m² due to high risk of life-threatening hyperkalemia 1, 2, 3
Spironolactone is contraindicated in patients with serum creatinine greater than 2.5 mg/dL in men or greater than 2.0 mg/dL in women, as these levels typically correspond to a GFR less than 30 mL/min/1.73 m² 2, 4
The American College of Cardiology recommends that spironolactone should not be initiated in patients with a baseline serum potassium greater than 5.0 mEq/L, regardless of GFR 5, 3

For patients with a GFR of 50 mL/min/1.73 m² or greater, the standard dosing of spironolactone is 25 mg once daily initially 1
For patients with a GFR between 30-49 mL/min/1.73 m², reduced dosing of 12.5-25 mg once daily or every other day is recommended 1, 2

When initiating spironolactone, potassium and renal function should be checked within 2-3 days of initiation, and again at 7 days after initiation 2, 5
Monitoring should continue at least monthly for the first 3 months, and every 3 months thereafter 2, 5
More frequent monitoring is recommended when adding or increasing doses of ACE inhibitors or ARBs 2, 5
For patients with a potassium level between 5.0-5.5 mEq/L, spironolactone can be continued with close monitoring 6
For patients with a potassium level greater than 5.5 mEq/L, the dose of spironolactone should be reduced by half and monitored closely 6
For patients with a potassium level greater than 6.0 mEq/L, spironolactone should be discontinued 6, 5

Potassium supplements should be discontinued when initiating spironolactone 2, 5
Patients should be counseled to avoid high-potassium foods and NSAIDs 2, 5
Spironolactone should be temporarily stopped during episodes of diarrhea, dehydration, or when loop diuretic therapy is interrupted 5
Triple therapy with ACE inhibitors, ARBs, and spironolactone should be avoided due to the high risk of hyperkalemia 5, 3

Patients with an estimated glomerular filtration rate of 30–49 mL/min/1.73 m² may be prescribed spironolactone only when a clear clinical indication exists—such as heart failure with reduced ejection fraction, resistant hypertension, or diabetic kidney disease with albuminuria—according to the 2023 Diabetes Care guidance. 7

After starting spironolactone in this population, serum potassium and renal function should be re‑checked at least monthly for the first three months, with ongoing surveillance every three months thereafter, to promptly detect hyper‑kalemia or renal decline (Diabetes Care, 2023). 7